A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration

Schroeder, Duane D.; Tankersley, Doanld L.; Lundblad, John L.

doi:10.1159/000464212

Cited by 5 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed that the H2Lz species ('intact' ISG) had been partially reduced and alkylated although at least one of the intraheavy chain disulfide bonds remained unreacted. It is this selective reaction of interheavy chain disulfide bonds which results in the loss of anticomplementary activity, described in Part I1 of this report [9].…”

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration

Schroeder¹,

Tankersley²,

Lundblad³

1981

Vox Sanguinis

Self Cite

View full text Add to dashboard Cite

Immune serum globulin (ISG) prepared by Cohn cold alcohol fractionation of pooled human plasma was reduced with dithiothreitol (DTT) and alkylated with iodoacetamide and other alkylating agents. Our results show that there are a few labile interheavy chain disulfide bonds in ISG which react rapidly under mild, nondissociating conditions. The extent of disulfide cleavage is controlled primarily by the ratio of DTT to ISG until about 4-5 disulfide bonds have been reduced. We report detailed studies on the variables of ISG concentration, DTT to ISG ratio, pH, and time, leading to a chemically modified ISG that has a controlled and limited number of reduced and alkylated disulfide bonds.

show abstract

Section: Discussionmentioning

confidence: 81%

“…We report here detailed studies on the reaction conditions for reduction and alkylation of ISG, leading to a modified immune serum globulin (MISG) which has a controlled and limited number of reduced and alkylated interchain disulfide bonds. The functional characterization of MISG is reported separately [9].…”

Section: Introductionmentioning

confidence: 99%

A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration

Schroeder¹,

Tankersley²,

Lundblad³

1981

Vox Sanguinis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chemically modified IVIGs were produced that were structurally intact, were low in anticomplement activity, and contained no IgG fragments. [9][10][11] Treatments of immunoglobulins with enzymes and chemical modification to suppress spontaneous complement activation had several unintended consequences. The treatments also reduced important antibody biological activities required for clinical efficacy.…”

mentioning

confidence: 99%

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations

Hooper¹

2008

Immunology and Allergy Clinics of North America

View full text Add to dashboard Cite

Since its first use in 1952, human immunoglobulin has been used to treat people who have inherited antibody deficiencies. This article summarizes IVIG clinical development in primary immunodeficient patients and manufacturing improvements introduced over time. Manufacturing improvements include purification procedures that have reduced the incidence of adverse events and improved clinical efficacy, as well as virus inactivation and removal steps that have increased safety from blood-borne infections. Current manufacturing procedures, IVIG production trends, and recent clinical trial results are also reviewed.

show abstract

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Hamblett

Senter²,

Chace³

et al. 2004

Clinical Cancer Research

1,032

View full text Add to dashboard Cite

Purpose: An antibody-drug conjugate consisting of monomethyl auristatin E (MMAE) conjugated to the anti-CD30 monoclonal antibody (mAb) cAC10, with eight drug moieties per mAb, was previously shown to have potent cytotoxic activity against CD30 ؉ malignant cells. To determine the effect of drug loading on antibody-drug conjugate therapeutic potential, we assessed cAC10 antibody-drug conjugates containing different drug-mAb ratios in vitro and in vivo.Experimental Design: Coupling MMAE to the cysteines that comprise the interchain disulfides of cAC10 created an antibody-drug conjugate population, which was purified using hydrophobic interaction chromatography to yield antibody-drug conjugates with two, four, and eight drugs per antibody (E2, E4, and E8, respectively). Antibody-drug conjugate potency was tested in vitro against CD30؉ lines followed by in vivo xenograft models. The maximum-tolerated dose and pharmacokinetic profiles of the antibody-drug conjugates were investigated in mice.Results: Although antibody-drug conjugate potency in vitro was directly dependent on drug loading (IC 50 values E8

show abstract

A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration

Cited by 5 publications

References 16 publications

A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration

A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Contact Info

Product

Resources

About